Bank of New York Mellon Corp increased its holdings in Bioventus Inc. (NYSE:BVS – Free Report) by 37.4% in the fourth quarter ...

Looking ahead, this article highlights the key trends expected to shape the regulatory landscape of pharmaceutical manufacturing in 2025. Regulatory agencies—including the U.S. Food and Drug ...

JPMorgan analyst Yang Huang initiated coverage of Ascentage Pharma (AAPG) with an Overweight rating and HK$52 price target The company’s Olverembatinib, having been approved for three CML ...

leading-edge R&D and radiopharmaceutical manufacturing infrastructure (PRNewsfoto/Actinium Pharmaceuticals, Inc.) Sandesh Seth, Actinium's Chairman and CEO, said, "We are honored to have this ...

WASHINGTON, March 24 (Reuters) - U.S. President Donald Trump said on Monday he will in the very near future announce tariffs on automobiles, aluminum and pharmaceuticals. Speaking to reporters at ...

Last year Merck agreed a similar licensing deal, also worth $2 billion, for Chinese biotech Hansoh Pharma’s experimental oral obesity drug, while yesterday Denmark’s Novo Nordisk (NVO ...

LabVantage Pharma is the only pre-configured and pre-validated pharmaceutical LIMS in the world. This greatly lowers the deployment cost (85%) and time (75%) compared to a traditional LIMS ...

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...

In this article, Ben Hargreaves asks whether there is particular potential for the technologies to revolutionise staff training and reduce costs in pharma manufacturing. Virtual reality (VR ...

Novo Nordisk will pay Lexicon Pharmaceuticals up to $1 billion to license its experimental obesity treatment. Lexicon eligible to receive up to $1 billion in upfront and development, regulatory ...